Prescribing information

 

   

Explore our range of useful resources below, designed to support you with your decision making. You can download the files to refer to later.

 

Front cover image of formulary app pack

Beovu® (brolucizumab) formulary application pack

Information intended to support you with your local formulary submission for Beovu.

Registration is required to access this resource.

Download resource

Image of Beovu business case template

Beovu Business Case

Information intended to support NHS professionals who are completing a business case for Beovu.

Registration is required to access this resource.

Download resource

Front cover image of Beovu Cohort business case template

Beovu Patient Cohort Business Case

Information intended to support NHS professionals who are completing a patient cohort business case for Beovu.

Registration is required to access this resource.

Download resource

 

 

Front cover image of Beovu COVID business case template

Beovu COVID Business Case

Information intended to support NHS professionals who are completing a business case for Beovu, in light of the COVID-19 situation.

Registration is required to access this resource.

Download resource

Image of Nice summary card

NICE summary card

Document detailing summary guidance for Beovu from NICE.

This document contains links which will take you to external websites over which Novartis Pharmaceuticals UK Limited has no ownership or control. Novartis Pharmaceuticals UK Limited accepts no responsibility for the content, accuracy, or your use of linked websites.

Download

Image of SMC summary

SMC guidance

Brolucizumab (Beovu®) is accepted for use within NHSScotland in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).

This link will take you to the SMC website, which is a non-Novartis website.

View full guidance

 

Request for budget impact model call

Request a conversation with a Novartis Account Manager to discuss the Beovu budget impact model, which supports an assessment of the impact of Beovu on service capacity and costs.

Request contact

 

Request value proposition call

Request a conversation with a Novartis Account Manager to view the Beovu value proposition, which provides an overview of the clinical, system and service benefits.

Request contact

Image of Beovu logo

If you are also a UK healthcare professional you can click below to view more information on ▼Beovu® (brolucizumab).

This link will take you to promotional information about Novartis products, therapy area materials and professional resources.

Show more

 

 

NHS, National Health Service; NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium.

Rate this content: 
0
No votes yet
UK | February 2021 | 104211

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]